EXICURE, INC. Contract Liability (Deferred Revenue)
EXICURE, INC. (XCUR) had Contract Liability (Deferred Revenue) of $0 as of 2022-12-31, per its 10-K filed 2023-03-27.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current › Deferred Revenue, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2023-03-27
- 2022-12-31: Contract with Customer, Liability, Current $0.00.
- 2022-09-30: Contract with Customer, Liability, Current $21.77M.
- 2022-06-30: Contract with Customer, Liability, Current $14.76M.
- 2022-03-31: Contract with Customer, Liability, Current $16.22M.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-03-27 |
| 2022-09-30 | $21.77M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $14.76M 10-Q · filed 2022-08-15 |
| 2022-03-31 | $16.22M 10-Q · filed 2022-05-16 |
| 2021-12-31 | $17.32M 10-K · filed 2023-03-27 |
| 2021-09-30 | $14.02M 10-Q · filed 2021-11-19 |
| 2021-06-30 | $7.27M 10-Q · filed 2021-08-12 |
| 2021-03-31 | $7.35M 10-Q · filed 2021-05-12 |
| 2020-12-31 | $8.34M 10-K · filed 2022-03-25 |
| 2020-09-30 | $8.48M 10-Q · filed 2020-11-12 |
| 2019-12-31 | $21.87M 10-K · filed 2021-03-11 |
| 2019-09-30 | $14.00K 10-Q · filed 2019-11-07 |
| 2019-06-30 | $541.00K 10-Q · filed 2019-08-08 |
| 2019-03-31 | $975.00K 10-Q · filed 2019-05-08 |
| 2018-12-31 | $0.00 10-K · filed 2020-03-10 |
| 2018-09-30 | $0.00 10-Q · filed 2018-11-06 |
| 2018-06-30 | $0.00 10-Q · filed 2018-08-06 |
| 2017-12-31 | $1.03M 10-K/A · filed 2019-09-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |